Evidence map›Paper›PMID 36482967›Full record

ArticlebioRxiv : the preprint server for biology2022

Human neutralizing antibodies to cold linear epitopes and to subdomain 1 of SARS-CoV-2.

Filippo Bianchini, Virginia Crivelli, Morgan E Abernathy, Concetta Guerra, Martin Palus, Jonathan Muri, Harold Marcotte, Antonio Piralla, Mattia Pedotti, Raoul De Gasparo and 36 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

46 authors at 16 institutions in 10 countries.

Filippo BianchiniInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Virginia CrivelliInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Morgan E AbernathyDepartment of Biology, Stanford University; Stanford, USA.
Concetta GuerraInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Martin PalusInstitute of Parasitology, Biology Centre of the Czech Academy of Sciences; Ceske Budejovice, Czech Republic.
Jonathan MuriInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Harold MarcotteDepartment of Biosciences and Nutrition, Karolinska Institutet; Huddinge, Sweden.
Antonio PirallaMicrobiology and Virology Department, Fondazione IRCCS Policlinico San Matteo; Pavia, Italy.
Mattia PedottiInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Raoul De GasparoInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Luca SimonelliInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Milos MatkovicInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Chiara ToscanoInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Maira BiggiogeroClinical Research Unit, Clinica Luganese Moncucco; Lugano, Switzerland.
Veronica CalvarusoClinical Research Unit, Clinica Luganese Moncucco; Lugano, Switzerland.
Pavel SvobodaInstitute of Parasitology, Biology Centre of the Czech Academy of Sciences; Ceske Budejovice, Czech Republic.
Tomás Cervantes RincónInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Tommaso FavaInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Lucie PodešvováInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Akanksha A ShanbhagInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Andrea CeloriaInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Jacopo SgrignaniInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Michal StefanikVeterinary Research Institute; Brno, Czech Republic.
Vaclav HönigInstitute of Parasitology, Biology Centre of the Czech Academy of Sciences; Ceske Budejovice, Czech Republic.
Veronika PranclovaInstitute of Parasitology, Biology Centre of the Czech Academy of Sciences; Ceske Budejovice, Czech Republic.
Tereza MichalcikovaCzech Centre of Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences; Vestec, Czech Republic.
Jan ProchazkaCzech Centre of Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences; Vestec, Czech Republic.
Giuditta GuerriniEuropean Commission, Joint Research Centre (JRC); Ispra, Italy.
Dora MehnEuropean Commission, Joint Research Centre (JRC); Ispra, Italy.
Annalisa CiabattiniLaboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies; University of Siena, Siena, Italy.
Hassan AbolhassaniDepartment of Biosciences and Nutrition, Karolinska Institutet; Huddinge, Sweden.
David JarrossayInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Mariagrazia UguccioniInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Donata MedagliniLaboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies; University of Siena, Siena, Italy.
Qiang Pan-HammarströmDepartment of Biosciences and Nutrition, Karolinska Institutet; Huddinge, Sweden.
Luigi CalzolaiEuropean Commission, Joint Research Centre (JRC); Ispra, Italy.
Daniel FernandezSarafan ChEM-H Macromolecular Structure Knowledge Center, Stanford University; Stanford, USA.
Fausto BaldantiDepartment of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia; Pavia, Italy.
Alessandra Franzetti-PellandaClinical Research Unit, Clinica Luganese Moncucco; Lugano, Switzerland.
Christian GarzoniInternal Medicine and Infectious Diseases, Clinica Luganese Moncucco; Lugano, Switzerland.
Radislav SedlacekCzech Centre of Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences; Vestec, Czech Republic.
Daniel RuzekInstitute of Parasitology, Biology Centre of the Czech Academy of Sciences; Ceske Budejovice, Czech Republic.
Luca VaraniInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Andrea CavalliInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Christopher O BarnesDepartment of Biology, Stanford University; Stanford, USA.
Davide F RobbianiInstitute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.
Università della Svizzera italiana · CHClinica Luganese Moncucco · CHCzech Academy of Sciences · CZCzech Academy of Sciences, Institute of Molecular Genetics · CZEuropean Commission · BEKarolinska Institutet · SEUniversity of Siena · ITChan Zuckerberg Initiative (United States) · USPoliclinico San Matteo Fondazione · ITRCVS Knowledge · GBSewanee: The University of the South · USSIB Swiss Institute of Bioinformatics · CHStanford University · USUniversity of Pavia · ITUniversity of Veterinary Sciences Brno · CZVeterinary Research Institute · CZ

Funding

A Synchrotron Radiation Structural Biology ResourcesP30GM133894 · NIGMS · STANFORD UNIVERSITY · PI KEITH O HODGSON · 2020 to 2026
$43.3M
Understanding B cell memory in response to diverse virus infectionsU19AI111825 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C · 2014 to 2023
$26.0M
University of Washington Arboviral Research Network (UWARN)U01AI151698 · NIAID · UNIVERSITY OF WASHINGTON · PI Michael Gale, PETER MACGARR RABINOWITZ · 2020 to 2026
$13.3M
Virology CoreP01AI138938 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C · 2018 to 2022
$8.4M
NIAID NIH HHS P01 AI138938NIAID NIH HHS U01 AI151698NIAID NIH HHS U19 AI111825NIGMS NIH HHS P30 GM133894
6 · The paper itself

Abstract

Emergence of SARS-CoV-2 variants diminishes the efficacy of vaccines and antiviral monoclonal antibodies. Continued development of immunotherapies and vaccine immunogens resilient to viral evolution is therefore necessary. Using coldspot-guided antibody discovery, a screening approach that focuses on portions of the virus spike that are both functionally relevant and averse to change, we identified human neutralizing antibodies to highly conserved viral epitopes. Antibody fp.006 binds the fusion peptide and cross-reacts against coronaviruses of the four One sentence summary: Broadly cross-reactive antibodies that protect from SARS-CoV-2 variants are revealed by virus coldspot-driven discovery.

Identifiers

PMID36482967
PMCPMC9727766
OpenAlexW4310123637

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.